SNSW(SH:688117) Ge Long Hui A P P·2026-02-11 08:04Core Viewpoint - The company, Shengnuo Biopharmaceutical (688117.SH), has participated in the national centralized procurement process for the first to eighth batches of drugs, marking a significant step in expanding its market presence and enhancing competitiveness in the peptide pharmaceutical market [1] Group 1: Procurement Participation - The company’s wholly-owned subsidiary, Chengdu Shengnuo Biopharmaceutical Co., Ltd., has engaged in the new round of centralized procurement organized by the state, which is the first nationwide unified continuation of centralized procurement for chemical drugs [1] - The company’s products, including Acetate Octreotide Injection (selected in the seventh batch), Acetate Atosiban Injection (selected in the eighth batch), and Somatostatin Injection (selected in the eighth batch), are among those proposed for selection in this new round of procurement [1] Group 2: Market Impact - The centralized procurement will prioritize the use of selected drugs by medical institutions, ensuring the completion of the agreed procurement volume [1] - The selection in this procurement round reflects the stability and reliability of the company’s drug quality, which is expected to further expand the sales scale of the selected products and increase market share [1] - The implementation of the procurement contract is anticipated to positively impact the company's operational development and strengthen its competitiveness in the peptide pharmaceutical market [1]